Lasa Supergeneri

Has Lasa Supergeneri declared dividend?

Lasa Supergenerics Ltd has declared a 2% dividend, amounting to ₹0.20 per share, with an ex-date of September 16, 2022. However, the company has faced significant negative returns across all periods, with total returns ranging from -34.27% to -81.34% over the past five years.

Lasa Supergenerics Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: 0.20<BR>- Ex-date: 16 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -47.32%, with a dividend return of 0%, resulting in a total return of -47.32%.<BR><BR>Over the past year, the price return was -34.27%, with a dividend return of 0%, leading to a total return of -34.27%.<BR><BR>In the last 2 years, the price return was -40.94%, with a dividend return of 0%, resulting in a total return of -40.94%.<BR><BR>For the 3-year period, the price return was -66.99%, with a dividend return of 0.60%, leading to a total return of -66.39%.<BR><BR>In the 4-year period, the price return was -81.34%, with a dividend return of 0.48%, resulting in a total return of -80.86%.<BR><BR>Over the last 5 years, the price return was -67.68%, with a dividend return of 0.87%, leading to a total return of -66.81%.<BR><BR>Overall, Lasa Supergenerics Ltd has declared a dividend, but the company has experienced significant negative returns across all periods, indicating a challenging financial performance despite the dividend declaration.

Who are the peers of the Lasa Supergeneri?

Lasa Supergeneri's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Sunil Healthcare, Vivo Bio Tech, and Vasundhara Rasy. Lasa Supergeneri has below average management risk and growth, with a 1-year return of -27.66%.

Peers: The peers of Lasa Supergeneri are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Sunil Healthcare, Vivo Bio Tech, and Vasundhara Rasy.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Rajnish Wellness, Vivo Bio Tech, and Vasundhara Rasy. Below Average management risk is present at Lasa Supergeneri, Sunil Healthcare. Excellent growth is noted for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Rajnish Wellness, while Below Average growth is seen at Lasa Supergeneri, Divi's Lab., Torrent Pharma, Sunil Healthcare, Vivo Bio Tech, and Vasundhara Rasy. Average capital structure is noted for Lasa Supergeneri, while Excellent capital structure is observed at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, and Good capital structure is found at Torrent Pharma and Vasundhara Rasy.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Rajnish Wellness has the lowest at -83.83%. Lasa Supergeneri's 1-year return is -27.66%, which is significantly lower than both extremes. Additionally, the six-month returns for Rajnish Wellness, Lasa Supergeneri, Sunil Healthcare, Vivo Bio Tech, and Vasundhara Rasy are negative.

Is Lasa Supergeneri overvalued or undervalued?

As of April 5, 2023, Lasa Supergeneri is considered overvalued with a high PE ratio of 47.70, negative ROCE of -7.08%, and a significant year-to-date return of -48.37%, indicating it is priced for growth despite poor financial performance compared to peers like Aarti Industries.

As of 5 April 2023, Lasa Supergeneri has moved from a grade of does not qualify to risky. The company is currently overvalued based on its high PE ratio of 47.70, which is significantly above the industry average, and a negative ROCE of -7.08%. Additionally, the EV to EBITDA ratio stands at 11.50, indicating a premium valuation relative to its earnings potential.<BR><BR>In comparison to peers, Lasa Supergeneri's PEG ratio of 0.43 suggests that it is priced for growth, yet its financial performance does not support such a valuation. For instance, a peer like Aarti Industries has a PE ratio of 25.00, which highlights the disparity in valuation metrics. Furthermore, the company has underperformed the Sensex significantly, with a year-to-date return of -48.37% compared to the Sensex's 5.60%, reinforcing the notion that Lasa Supergeneri is overvalued in its current state.

What is the technical trend for Lasa Supergeneri?

As of April 25, 2025, Lasa Supergeneri exhibits a strong bearish trend supported by negative MACD, Bollinger Bands, and moving averages across multiple time frames.

As of 25 April 2025, the technical trend for Lasa Supergeneri has changed from mildly bearish to bearish. The current stance is bearish with strong indicators supporting this view. The MACD is bearish on both the weekly and monthly time frames, and the Bollinger Bands also indicate a bearish trend in both time frames. Daily moving averages confirm the bearish sentiment. The KST is bearish on both weekly and monthly charts, while the Dow Theory shows a mildly bearish stance on the weekly and monthly time frames. The OBV reflects a mildly bearish condition as well. Overall, the combination of these indicators suggests a strong bearish outlook for Lasa Supergeneri.

Who are in the management team of Lasa Supergeneri?

As of March 2022, the management team of Lasa Supergeneri includes Omkar P Herlekar (Chairman & Managing Director), Shivanand Hedge (Whole-time Director), and five Independent Directors: Hardesh Tolani, Ajay Sukhwani, Ekta Gurnasinghani, and Manali Bhagtani, along with Mitti M Jain (Company Secretary & Compliance Officer).

As of March 2022, the management team of Lasa Supergeneri includes the following individuals:<BR><BR>1. Omkar P Herlekar - Chairman & Managing Director<BR>2. Shivanand Hedge - Whole-time Director<BR>3. Hardesh Tolani - Independent Director<BR>4. Ajay Sukhwani - Independent Director<BR>5. Ekta Gurnasinghani - Independent Director<BR>6. Mitti M Jain - Company Secretary & Compliance Officer<BR>7. Manali Bhagtani - Independent Director<BR><BR>These members play various roles in the governance and management of the company.

What does Lasa Supergeneri do?

Lasa Supergenerics Ltd is a micro-cap pharmaceutical company focused on manufacturing and trading chemicals, APIs, and pharmaceuticals. As of March 2025, it reported net sales of 391 Cr and a net profit of -143 Cr, with a market cap of INR 61 Cr.

Overview:<BR>Lasa Supergenerics Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, primarily engaged in manufacturing and trading chemicals, APIs, and pharmaceuticals.<BR><BR>History:<BR>Lasa Supergenerics Limited was incorporated on March 11, 2016. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 391 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -143 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 61 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 40.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.02 <BR>Return on Equity: 1.78% <BR>Price to Book: 0.73 <BR><BR>Contact Details:<BR>Address: C-105 MIDC, Mahad Raigad Maharashtra : 402301 <BR>Tel: 91-2145-232101/232202 <BR>Email: cs@lasalabs.com <BR>Website: http://www.lasalabs.com

Who are the top shareholders of the Lasa Supergeneri?

The top shareholders of Lasa Supergeneri are primarily its promoters, with Omkar Pravin Herlekar holding 53.65% of the shares. Individual investors own 34.08%, and there are currently no mutual funds or foreign institutional investors involved.

The top shareholders of Lasa Supergeneri primarily consist of its promoters. The largest individual shareholder is Omkar Pravin Herlekar, who holds 53.65% of the shares. Additionally, individual investors collectively own 34.08% of the company. There are no mutual funds or foreign institutional investors (FIIs) holding shares in Lasa Supergeneri at this time.

How big is Lasa Supergeneri?

As of 24th July, Lasa Supergenerics Ltd has a market capitalization of 57.00 Cr and reported net sales of 142.45 Cr with a loss of 14.76 Cr over the latest four quarters. As of March 2024, shareholder's funds were 96.68 Cr and total assets were valued at 150.87 Cr.

As of 24th July, Lasa Supergenerics Ltd has a market capitalization of 57.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Lasa Supergenerics reported net sales of 142.45 Cr. However, the company experienced a loss of 14.76 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where the shareholder's funds amounted to 96.68 Cr and total assets were valued at 150.87 Cr.

Are Lasa Supergeneri latest results good or bad?

Lasa Supergenerics' latest results show a significant turnaround in Profit After Tax, which rose to Rs 9.07 crore, a 198% increase year-on-year. However, the company faces challenges with a 35.12% drop in net sales and negative operating profit, indicating mixed overall performance.

Lasa Supergenerics' latest results present a mixed picture. On one hand, the company has achieved a significant turnaround in its Profit After Tax (PAT), which reached Rs 9.07 crore, showing a remarkable year-on-year growth of nearly 198%. This is a positive indicator of improved profitability compared to the previous year when it reported a loss.<BR><BR>However, there are notable challenges as well. The net sales for the quarter fell sharply by 35.12% year-on-year, marking the lowest sales figure in the last five quarters. Additionally, the operating profit was negative, at Rs -0.50 crore, which also reflects a decline in operational performance. The operating profit margin turned negative at -2.50%, and the earnings per share (EPS) dropped to Rs -4.22, indicating declining profitability for shareholders.<BR><BR>In summary, while the increase in PAT is a positive development, the significant drop in sales and negative operating profit suggest that Lasa Supergenerics is facing considerable challenges. Overall, the results can be seen as a mix of good and bad, with more emphasis on the difficulties the company is currently experiencing.

How has been the historical performance of Lasa Supergeneri?

Lasa Supergeneri has experienced significant fluctuations in financial performance, with net sales declining from a peak of 202.38 Cr in March 2021 to 142.45 Cr by March 2025, and operating profit turning negative in March 2023 before improving slightly to 6.27 Cr in March 2025. The company has also seen a decrease in reserves and earnings per share, with a negative profit before tax of -19.38 Cr in March 2025.

Answer:<BR>The historical performance of Lasa Supergeneri shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Lasa Supergeneri's net sales have varied, peaking at 202.38 Cr in March 2021 but declining to 142.45 Cr by March 2025, with a notable drop from 137.13 Cr in March 2022. Total operating income followed a similar trend, reflecting the same values as net sales. Raw material costs increased to 108.10 Cr in March 2025 from 79.28 Cr in March 2024, while total expenditure rose to 136.18 Cr in March 2025, indicating rising operational costs. Operating profit, which was positive at 47.22 Cr in March 2021, turned negative in March 2023 at -6.59 Cr and improved to 6.27 Cr by March 2025. Profit before tax remained negative, reaching -19.38 Cr in March 2025, with profit after tax also negative at -14.76 Cr. The company's equity capital remained stable at 50.10 Cr from March 2023 to March 2025, but reserves have significantly decreased from 107.96 Cr in March 2022 to 33.61 Cr in March 2025. The earnings per share have shown a downward trend, with a loss of -2.95 in March 2025 compared to a profit of 5.6 in March 2021. Cash flow from operating activities was positive at 2.00 Cr in March 2024, but the overall cash position has deteriorated, with closing cash and cash equivalents at 0.00 Cr in March 2024.

Should I buy, sell or hold Lasa Supergeneri?

When is the next results date for Lasa Supergenerics Ltd?

Lasa Supergenerics Ltd will announce its results on 13 February 2026.

Lasa Supergenerics Ltd is scheduled to declare its results on 13 February 2026.

Why is Lasa Supergenerics Ltd falling/rising?

As of 11-Feb, Lasa Supergenerics Ltd's stock price is at 9.01, showing a slight recent increase but significant declines over the past year and three years, indicating persistent underperformance compared to the market. Investor participation is also declining, contributing to the stock's volatility.

As of 11-Feb, Lasa Supergenerics Ltd's stock price is currently at 9.01, reflecting a slight increase of 0.01 (0.11%). The stock has shown a positive trend over the last two days, gaining a total of 1.46% during this period. However, despite this recent uptick, the stock has underperformed its sector by 0.72% today.<BR><BR>In terms of longer-term performance, the stock has faced significant declines, with a year-to-date decrease of 3.84% and a staggering 62.69% drop over the past year. Additionally, over the last three years, the stock has fallen by 65.81%, while the benchmark Sensex has increased by 38.81% during the same period. This stark contrast indicates a persistent underperformance relative to the broader market.<BR><BR>Investor participation appears to be declining, as evidenced by a 23.87% drop in delivery volume compared to the five-day average. This reduction in trading activity may contribute to the stock's volatility and overall performance. Furthermore, while the current price is above the five-day moving average, it remains below the 20-day, 50-day, 100-day, and 200-day moving averages, suggesting that the stock is not in a strong upward trend.<BR><BR>In summary, while Lasa Supergenerics Ltd has experienced a minor rise in price recently, its overall performance remains weak, characterized by significant declines over various time frames and decreasing investor participation.

Which are the latest news on Lasa Supergeneri?